Richard Foust serves as President and CEO of MicroTransponder, bringing over 20 years of global leadership experience in the healthcare industry. He has deep experience in commercialization, portfolio strategy, and cross-functional senior leadership. Mr. Foust previously served as Chief Commercial Officer at Velano Vascular (acquired by Beckton Dickinson) and held multiple senior roles at Abbott (NYSE: ABT), including as a Director in the Global Endovascular Business Unit and as Marketing Director of the EMEA Coronary Business. Earlier in his career, he held leadership roles at Analyte Healthcare and Guidant (NYSE: GDT). He holds a BS in Applied Physics from Emory University and an MSME in Bioengineering from Georgia Institute of Technology.

Dana Mead has more than three decades of executive leadership experience in healthcare and currently serves on the boards of Inspire Medical (NYSE: INSP), Pulmonx (Nasdaq: LUNG), Calyxo, Cerapedics, and BVI Medical. He previously served on the boards of Inari Medical (Nasdaq: NARI) prior to its acquisition by Stryker, Intersect ENT (Nasdaq: XENT) prior to its acquisition by Medtronic, and Teladoc (NYSE: TDOC). Mr. Mead served as President and CEO of HeartFlow from 2019-2021 and President and CEO of BVI from 2016-2019, following 13 years in key senior management roles at Guidant (NYSE: GDT). Mr. Mead also served as a life sciences partner at leading venture firm Kleiner Perkins Caufield & Byers, where he advised medtech companies on strategy and commercialization. He holds a BA from Lafayette College and an MBA from the University of Southern California.

Casey Tansey has served as Managing Partner at U.S. Venture Partners since 2005 and brings over 30 years of entrepreneurial and executive experience in the medical device sector where he helps shape strategy, partnership development, and organizational growth. Mr. Tansey currently sits on the boards of several health technology companies including HeartFlow (Nasdaq: HTFL), Shoulder Innovations (NYSE: SI), and Inspire Medical (NYSE: INSP). He previously served on the boards of Intersect ENT (Nasdaq: XENT) prior to its acquisition by Medtronic and SentreHEART prior to its acquisition by Atricure. Mr. Tansey has held several chief executive roles including at Epicor Medical where he guided the company through its acquisition by St. Jude Medical and at Heartport prior to its acquisition by Johnson & Johnson. Mr. Tansey holds both a BS and an MBA from the College of Notre Dame in Belmont, California.

Cynthia Lucchese is a seasoned executive and corporate director with over three decades of financial, operational, and corporate governance experience in the healthcare industry. Ms. Lucchese currently serves on the boards of CooperCompanies (Nasdaq: COO) and BVI Medical and previously served on the boards of Inari Medical (Nasdaq: NARI) prior to its acquisition by Stryker, Relievant Medsystems prior to its acquisition by Boston Scientific, Hanger (NYSE: HNGR) prior to its acquisition by Patient Square Capital, and Intersect ENT (Nasdaq: XENT) prior to its acquisition by Medtronic. Ms. Lucchese recently served as Chief Strategy Officer for Penske Entertainment and prior to that Chief Administrative Officer and CFO. She previously held Senior Vice President and CFO roles at Hillenbrand (NYSE: HI) and Thoratec (Nasdaq: THOR) in addition to several senior financial positions at Guidant (NYSE: GDT). Ms. Lucchese is a Certified Public Accountant (inactive) and earned a BS in Accounting and an MBA from Indiana University.

Bill Harrington, MD has served as a Managing Partner at Osage University Partners (OUP) since 2012 where he oversees life science investing activities across biotechnology and medical devices. Prior to OUP, Dr. Harrington spent 14 years as a General Partner at Three Arch Partners focused primarily on medical devices and was a founding investor and board member at Nevro (NASDAQ: NVRO). He currently sits on the boards of Neuros Medical, Hyalex Orthopedics, Transposon Therapeutics and Medisix Therapeutics. Dr. Harrington previously practiced medicine as an interventional radiologist. He is a CFA Chartholder and holds a BS from Tufts University, an MD from Harvard Medical School, and an MBA from the Haas School of Business at UC Berkeley.

Edward Hanlon serves as an Investment Manager at Gilde Healthcare where he focuses on deal origination, assessment, and portfolio management in disruptive clinical and growth-stage medical device companies. Before joining Gilde, Mr. Hanlon worked in healthcare advisory at Health Advances, where he provided strategic and commercial support to emerging healthcare innovators in medical devices, biopharmaceuticals, healthtech, and diagnostics. Mr. Hanlon also serves on the board of VS3 Medical and has been involved with several medical device ventures including Shoulder Innovations (NYSE: SI) and Nalu Medical (pending acquisition by Boston Scientific). He holds a BS in Biology from Duke University.

Maxwell Bikoff serves as Managing Director at Longitude Capital, focusing on investments in medical technologies and solutions. Mr. Bikoff currently serves on the board of Polares Medical and is a board observer at FIRE1. He previously served on the board of Kestra Medical Technologies (NASDAQ: KMTS), and as a board observer at Amphora (acquired by Hologic), Bolt Medical (acquired by Boston Scientific), Ceribell (NASDAQ: CBLL), Eargo (NASDAQ: EAR), Endogenex, LimFlow (acquired by Inari), Nalu Medical (pending acquisition by Boston Scientific), and RxSight (NASDAQ: RXST). He was actively involved in Longitude’s investment in Axonics (NASDAQ: AXNX) and PROCEPT BioRobotics (NASDAQ: PRCT). Prior to joining Longitude Capital in 2016, Mr. Bikoff held a series of strategy, finance, and operating roles at Cardinal Health (NYSE: CAH). Mr. Bikoff began his career in Deloitte Consulting’s Life Sciences Strategy practice and holds a BSE in Biomedical Engineering from Duke University.

Bunker Curnes joined MicroTransponder with 15 years of experience in finance and operations roles in various industries. He has worked with MicroTransponder since 2011 in various financial roles before becoming CFO in 2020. Prior to joining MicroTransponder, Mr. Curnes worked as the CFO for HEMCO Development. Previously, he worked at the Boston Consulting Group on a variety of projects across the healthcare, energy, and retail consumer sectors. Mr. Curnes holds a BS in Mechanical Engineering from the University of Notre Dame and an MBA from the Fuqua School of Business at Duke University.

Jordan Curnes co-founded MicroTransponder and has helped shape its business strategy and commercialization since the company’s founding in 2007. His experience includes management consulting at Huron Consulting Group with a focus on large healthcare corporations. Mr. Curnes remains active in investing and entrepreneurial mentorship. He holds a BBA in Finance from the University of Notre Dame and an MBA from the Fuqua School of Business at Duke University.